1. PI3K/Akt/mTOR
  2. Akt
  3. PX-316

PX-316 is an Akt inhibitor. PX-316 can phosphorylate Akt, but does not inhibit the phosphorylation of PDK1 or PKC. PX-316 uniquely increases the expression of a group of mitochondrial-related genes. PX-316 can be used for the study of colon cancer and breast cancer.

For research use only. We do not sell to patients.

PX-316

PX-316 Chemical Structure

CAS No. : 253440-95-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products

View All Akt Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PX-316 is an Akt inhibitor. PX-316 can phosphorylate Akt, but does not inhibit the phosphorylation of PDK1 or PKC. PX-316 uniquely increases the expression of a group of mitochondrial-related genes. PX-316 can be used for the study of colon cancer and breast cancer[1].

IC50 & Target

Akt

 

In Vitro

PX-316 (0-15 μM, 2 h) specifically inhibits Akt (IC50 = 1.7 μM) activation in HT-29 human colon cancer cells without affecting upstream kinase PDK1 or related kinase PKC[1].
PX-316 (0.5-20 μM, 3 days) inhibits the proliferation of MCF-7 and HT-29 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: HT-29 human colon cancer cells
Concentration: 0 μM, 5 μM, 10 μM, 15 μM
Incubation Time: 2 h
Result: Inhibited EGF-induced Akt phosphorylation (phosphorylation of Ser473 site) in a concentration-dependent manner with an IC50 value of 1.7 μM, but did not inhibit PDK1 phosphorylation (Ser241 site) or PKC phosphorylation (Thr638/641 site).
In Vivo

PX-316 (37.5-150 mg/kg, i.p., once) effectively inhibits the Akt signaling pathway and its downstream targets in HT-29 cells xenograft mice, and the inhibitory effect is maintained even after multiple administrations[1].
PX-316 (50-150 mg/kg, i.p., once for 4-10 days) demonstrates dose- and regimen-dependent antitumor activity in two different mice xenograft models of human tumors (MCF-7 and HT-29)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: HT-29 colon cancer cells(107)were injected subcutaneously into the flanks of male severe combined immunodeficient (scid) mice[1].
Dosage: 37.5 mg/kg, 75 mg/kg, 150 mg/kg
Administration: I.p., once
Result: A single administration of 150 mg/kg inhibited Akt (Ser473) phosphorylation in tumors by up to 78% at 10 hours, recovering to 34% inhibition after 48 hours.
The half-maximal inhibitory dose (ID50) for Akt phosphorylation in tumors was 80 mg/kg, while the ID50 for normal tissue (spleen) was 128 mg/kg.
At a concentration of 150 mg/kg, phosphorylation of GSK-3β (Ser9), a downstream target of Akt, was also inhibited, with inhibition rates of 53% and 77% at 5 hours and 24 hours, respectively.
At a dose of 75 mg/kg, whether administered once daily for 5 consecutive days or once every 3 days for 5 consecutive days, Akt activity was consistently inhibited (inhibition rate of 70%-80%).
Animal Model: MCF-7 human breast cancer cells (107 cells) were mixed with Matrigel and subcutaneously injected into the flank of female SCID mice. One day before tumor cell inoculation, mice were subcutaneously implanted with 60-day sustained-release 17-β-estradiol pellets to support the growth of this estrogen-dependent tumor[1].
Dosage: 50 mg/kg, 75 mg/kg, 100 mg/kg
Administration: I.p., once daily for 10 days, 10 days and 5 days, respectively
Result: 75 mg/kg showed a good inhibitory effect (T/C = 20%), while 100 mg/kg showed a slightly weaker effect (T/C = 39%).
Animal Model: HT-29 human colon cancer cells (107 cells) were subcutaneously injected into the flank of SCID mice[1].
Dosage: 100 mg/kg, 150 mg/kg
Administration: I.p., once daily for 4 days
Result: Caused growth inhibition of 5-day HT-29 colon cancer xenografts when administered for 4 days IP at 150 mg/kg/day (T/C33.3%, P<0.05) but no activity at 100 mg/kg/day.
Molecular Weight

584.72

Formula

C28H57O10P

CAS No.
SMILES

CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP(O[C@H]1[C@@H]([C@H]([C@@H](C[C@H]1O)O)O)O)(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PX-316
Cat. No.:
HY-119134
Quantity:
MCE Japan Authorized Agent: